|
1
|
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
|
Antimicrob Agents Chemother
|
2007
|
1.91
|
|
2
|
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
|
Virology
|
2006
|
1.49
|
|
3
|
Maturation inhibitors: a new therapeutic class targets the virus structure.
|
AIDS Rev
|
2007
|
1.45
|
|
4
|
The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.
|
Expert Opin Investig Drugs
|
2005
|
1.15
|
|
5
|
Effect of ambient temperature on marathon pacing is dependent on runner ability.
|
Med Sci Sports Exerc
|
2008
|
1.08
|
|
6
|
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.
|
PLoS One
|
2007
|
1.06
|
|
7
|
Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
|
J Acquir Immune Defic Syndr
|
2011
|
0.99
|
|
8
|
Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma.
|
Drug Metab Dispos
|
2006
|
0.94
|
|
9
|
Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients.
|
Antimicrob Agents Chemother
|
2011
|
0.93
|
|
10
|
Effects of exposure to a 50 Hz electric field on plasma levels of lactate, glucose, free Fatty acids, triglycerides and creatine phosphokinase activity in hind-limb ischemic rats.
|
J Vet Med Sci
|
2005
|
0.93
|
|
11
|
Anti-AIDS agents 65: investigation of the in vitro oxidative metabolism of 3',4'-Di-O-(-)-camphanoyl-(+)-cis-khellactone derivatives as potent anti-hiv agents.
|
Drug Metab Dispos
|
2005
|
0.91
|
|
12
|
Glucuronidation of anti-HIV drug candidate bevirimat: identification of human UDP-glucuronosyltransferases and species differences.
|
Drug Metab Dispos
|
2006
|
0.80
|
|
13
|
An oral human drug absorption study to assess the impact of site of delivery on the bioavailability of bevirimat.
|
J Clin Pharmacol
|
2009
|
0.78
|
|
14
|
The absorption, distribution, metabolism and elimination of bevirimat in rats.
|
Biopharm Drug Dispos
|
2008
|
0.77
|
|
15
|
Effect of a 50 Hz electric field on plasma ACTH, glucose, lactate, and pyruvate levels in stressed rats.
|
Bioelectromagnetics
|
2004
|
0.77
|
|
16
|
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
|
Platelets
|
2003
|
0.75
|
|
17
|
60 Hz electric field upregulates cytosolic Ca2+ level in mouse splenocytes stimulated by lectin.
|
Bioelectromagnetics
|
2004
|
0.75
|